Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, and Acute Lymphoblastic Leukemia research.
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
CRISPR-engineered T cells in patients with refractory cancer
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
Global Manufacturing of CAR T Cell Therapy
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Engineered T cells: the promise and challenges of cancer immunotherapy
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Gene Editing of <i>CCR5</i> in Autologous CD4 T Cells of Persons Infected with HIV
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells